Emerging strategies for pegylated interferon combination therapy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire virus in vitro could ultimately facilitate the identification of therapies directly targeting viral replication. Several therapies are presently in development. Taribavirin hydrochloride (Viramidine®, Valeant Pharmaceutical International, Singapore), a ribavirin prodrug, has shown promise, although the rate of sustained virologic response with this agent has been disappointing. The next generation of antivirals will consist of protease and polymerase inhibitors, a number of which are undergoing investigation, initially as monotherapy and subsequently in combination with pegylated interferon and ribavirin. Challenges include the prevention of recurrent HCV infection in liver-transplant recipients and development of a safe and effective HCV vaccine.

Original languageEnglish
JournalNature Clinical Practice Gastroenterology and Hepatology
Volume4
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Hepacivirus
Interferons
Ribavirin
Virus Diseases
Singapore
Prodrugs
Protease Inhibitors
Antiviral Agents
Immune System
Therapeutics
Vaccines
Viruses
Liver
Pharmaceutical Preparations
ribavirin amidine
Sustained Virologic Response
In Vitro Techniques
Transplant Recipients

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Emerging strategies for pegylated interferon combination therapy. / Schiff, Eugene R.

In: Nature Clinical Practice Gastroenterology and Hepatology, Vol. 4, No. SUPPL. 1, 01.01.2007.

Research output: Contribution to journalArticle

@article{5921f053954245b3bb922799343476fc,
title = "Emerging strategies for pegylated interferon combination therapy",
abstract = "Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire virus in vitro could ultimately facilitate the identification of therapies directly targeting viral replication. Several therapies are presently in development. Taribavirin hydrochloride (Viramidine{\circledR}, Valeant Pharmaceutical International, Singapore), a ribavirin prodrug, has shown promise, although the rate of sustained virologic response with this agent has been disappointing. The next generation of antivirals will consist of protease and polymerase inhibitors, a number of which are undergoing investigation, initially as monotherapy and subsequently in combination with pegylated interferon and ribavirin. Challenges include the prevention of recurrent HCV infection in liver-transplant recipients and development of a safe and effective HCV vaccine.",
author = "Schiff, {Eugene R}",
year = "2007",
month = "1",
day = "1",
doi = "10.1038/ncpgasthep0691",
language = "English",
volume = "4",
journal = "Nature Reviews Gastroenterology and Hepatology",
issn = "1759-5045",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Emerging strategies for pegylated interferon combination therapy

AU - Schiff, Eugene R

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire virus in vitro could ultimately facilitate the identification of therapies directly targeting viral replication. Several therapies are presently in development. Taribavirin hydrochloride (Viramidine®, Valeant Pharmaceutical International, Singapore), a ribavirin prodrug, has shown promise, although the rate of sustained virologic response with this agent has been disappointing. The next generation of antivirals will consist of protease and polymerase inhibitors, a number of which are undergoing investigation, initially as monotherapy and subsequently in combination with pegylated interferon and ribavirin. Challenges include the prevention of recurrent HCV infection in liver-transplant recipients and development of a safe and effective HCV vaccine.

AB - Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire virus in vitro could ultimately facilitate the identification of therapies directly targeting viral replication. Several therapies are presently in development. Taribavirin hydrochloride (Viramidine®, Valeant Pharmaceutical International, Singapore), a ribavirin prodrug, has shown promise, although the rate of sustained virologic response with this agent has been disappointing. The next generation of antivirals will consist of protease and polymerase inhibitors, a number of which are undergoing investigation, initially as monotherapy and subsequently in combination with pegylated interferon and ribavirin. Challenges include the prevention of recurrent HCV infection in liver-transplant recipients and development of a safe and effective HCV vaccine.

UR - http://www.scopus.com/inward/record.url?scp=33846410735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846410735&partnerID=8YFLogxK

U2 - 10.1038/ncpgasthep0691

DO - 10.1038/ncpgasthep0691

M3 - Article

C2 - 17235281

AN - SCOPUS:33846410735

VL - 4

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

SN - 1759-5045

IS - SUPPL. 1

ER -